Description
DHB Oral (1-Testosterone Cypionate, Dihydroboldenone Cypionate) is the oral variant of a Boldenone derivative with additional cypionate esterification and 1-dehydro modification. The substance is related to Boldenone (Equipoise) but structurally more stable against aromatization.
Per study reports DHB binds to the androgen receptor with moderate to high affinity. The central property: no aromatization to estradiol, excluding water retention and gynecomastia research findings. Unlike Equipoise (which aromatizes weakly), the DHB profile stays completely dry.
In recreational research practice DHB Oral is positioned as a middle-ground compound between mild Anavar and aggressive Masteron. Anabolic action is moderate, androgenic activity low to moderate, side effect profile moderate compared to classical 17α-methyl steroids.
Pharmacokinetically orally bioavailable with about 6-8 hour half-life. Bioavailability moderate - DHB Oral isn’t 17α-methylated, making it less hepatotoxic but also reducing bioavailability.
Known effects in studies: dry muscle quality, low water retention, mild HPG suppression. Hepatotoxicity lower than under classical orals due to missing 17α-methyl group.
You can order DHB Oral as oral tablets in one bottle with 10mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
DHB Oral is considered a moderate compound between mild Anavar and aggressive Masteron per study reports, yet still sits clearly in the upper range of the risk scale. The effects documented in the literature are more moderate than under classical 17α-methyl steroids.
Documented in studies and the user literature:
- Liver strain: DHB Oral is not 17α-methylated, so hepatotoxicity is described in the literature as lower than under classical orals, but liver marker monitoring remains sensible.
- Lipid profile: as is usual with androgenic compounds, an unfavorable shift of the lipid profile is documented in the literature.
- Suppression of natural production: a mild but present HPG suppression is described in the literature.
- Androgenic effects: as a non-aromatizing compound, androgenic effects without an estrogen counter-effect are documented in the literature.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- 17beta-Hydroxy-5alpha-androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties - Toxicology Letters 2006, Friedel et al: core characterization study in rats finding that 1-testosterone (dihydroboldenone) has high AR affinity and pronounced anabolic-androgenic potency along with increased liver weight.
- Prohormone supplement 3beta-hydroxy-5alpha-androst-1-en-17-one enhances resistance training gains but impairs user health - Journal of Applied Physiology 2014: randomized placebo-controlled trial on the 1-testosterone prohormone showing significant effects on lean mass and strength but adverse changes in lipid, liver, and kidney markers.
- Seized designer supplement named “1-Androsterone”: Identification as 3beta-hydroxy-5alpha-androst-1-en-17-one and its urinary elimination - Steroids 2011, Parr et al: analytical study identifying the 1-testosterone prohormone in a seized supplement and characterizing its urinary elimination including conversion to 1-testosterone.
- Pharmacology of anabolic steroids - British Journal of Pharmacology 2008, Kicman: comprehensive review of pharmacology, metabolism, and toxicology of anabolic steroids including the 1-testosterone class.
- Designer steroids - over-the-counter supplements and their androgenic component: review of an increasing problem - Andrology 2015, Rahnema et al: review article on designer steroids including 1-testosterone derivatives with focus on hepatotoxicity and endocrine side effects.
